Mechanistically, oncogenic mutations, amplifications, and tumor suppressor inactivation drive advanced prostate cancer progression in addition to the AR signaling pathway.4, 5, 6, 7 Therefore, uncovering and targeting core oncogenic drivers may offer new avenues for managing lethal prostate cancer. This evidence concerns the gene AR and prostate cancer.